Title: "Development of a Scalable Route for ABBV-576 Leveraging Multiple Process Technologies."

Sponsored by: AbbVie and Org Synth

Hosted by: Brett VanVeller

Bio: Jeff Kallemeyn obtained a B.S in Chemistry from Calvin University and a Ph.D. in Chemistry from the University of Illinois at Urbana-Champaign where his research with Scott Denmark focused on silanol-based cross-coupling reactions. In 2007, Jeff joined AbbVie Process R&D (at the time Abbott Laboratories) where he is currently a Senior Research Fellow. At AbbVie Jeff has impacted several programs, notably contributing to the commercial synthetic route development of both Glecapravir and Pibrentasvir, the drug substances of the Hepatitis C treatment Mavyret® which was recognized with an ACS Heroes of Chemistry award in 2023. Jeff also advises project teams on mutagenic impurity control strategies and regulatory starting materials.